Equities

Nanosonics Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Nanosonics Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)3.60
  • Today's Change0.02 / 0.56%
  • Shares traded654.82k
  • 1 Year change+3.75%
  • Beta1.6181
Data delayed at least 20 minutes, as of Feb 17 2026 05:10 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Nanosonics Limited is an Australia-based infection prevention company. The Company's principal activities include the manufacturing and distribution of the trophon ultrasound probe disinfector and its associated consumables and accessories. It is focused on the research, development, and commercialization of infection control and decontamination products and related technologies. Trophon technology includes high-frequency ultrasonic vibrations that generate a sonically activated hydrogen peroxide (H2O2) mist that kills bacteria, fungi, and viruses. Its products include trophon2, Nanosonics Auditpro, and trophon EPR. Its trophon2 includes AcuTrace radio frequency identification (RFID) technology, which enables digital record keeping and captures disinfection data. Nanosonics AuditPro is an automated digital system that combines clinician infection prevention decision making, with the Trophon 2 device infection control workflow data, and patient procedure information.

  • Revenue in AUD (TTM)198.63m
  • Net income in AUD20.68m
  • Incorporated2000
  • Employees470.00
  • Location
    Nanosonics Ltd7-11 Talavera Road, Macquarie ParkSYDNEY 2113AustraliaAUS
  • Phone+61 28063-1600
  • Fax+61 29418-3743
  • Websitehttps://www.nanosonics.com.au/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Aroa Biosurgery Ltd77.16m-1.55m236.65m261.00--3.00140.673.07-0.0045-0.00450.22360.22850.84321.563.08---1.70-8.53-1.85-9.7585.0782.71-2.01-15.205.740.31420.0706--22.6327.5664.12--14.62--
Orthocell Ltd8.85m-8.57m249.60m----15.37--28.20-0.0375-0.03750.03970.05990.28622.319.20---27.70-28.14-34.17-33.4768.9871.87-96.78-167.824.78--0.0381--36.4161.65-19.30--45.43--
Saluda Medical Inc-100.00bn-100.00bn257.06m--------------------------------------------------36.13---52.62------
Paragon Care Ltd3.62bn20.57m331.06m0.0016.101.006.570.09150.01240.01242.180.19933.0211.9010.33--1.721.794.474.079.048.900.56880.60810.61551.770.4699--21.7273.23151.52--18.34--
EchoIQ Ltd101.41k-13.26m349.78m----15.17--3,449.13-0.0226-0.02260.00020.03530.0064--0.6446---83.87-68.78-89.84-81.95-----13,078.12-3,892.98----0.00--127.89-31.65-145.19---16.56--
EBR Systems Inc963.94k-63.35m355.53m----6.50--368.83-0.1692-0.16920.00250.12150.0074--0.4935---48.75-60.71-53.75-74.7645.20---6,572.14--7.01-15.000.5131-------16.44--2.46--
Polynovo Ltd127.73m13.21m639.03m301.0048.517.6740.165.000.01910.01910.18370.12051.080.3675.88424,352.2011.192.1714.292.7196.6394.8910.352.102.257.870.17070.0021.9641.91151.17--9.45--
Imricor Medical Systems Inc1.06m-50.86m661.15m----20.23--624.72-0.1881-0.18810.00380.10180.02371.132.64---113.72-103.39-123.12-119.90-133.44-154.65-4,806.09-2,687.8525.62-1.110.5073--55.868.44-31.23---26.55--
Nanosonics Ltd.198.63m20.68m1.09bn470.0053.535.1837.785.470.06690.06690.64250.69130.77922.235.05422,612.808.116.489.457.5378.2277.9310.418.695.19--0.03530.0016.8314.7059.3915.3235.13--
4DMedical Ltd5.85m-30.07m2.17bn----27.54--369.91-0.0714-0.07140.01380.1380.05450.48580.8787---27.99-32.98-34.63-40.3892.0786.20-513.72-1,237.520.8383--0.0629--55.9136.5616.42--3.07--
Ansell Ltd2.84bn191.43m4.67bn15.72k24.701.6615.461.641.311.3119.5019.510.60932.119.25180,748.004.145.334.866.3842.1638.276.807.981.138.620.293948.3023.714.4232.81-8.531.350.4863
Data as of Feb 17 2026. Currency figures normalised to Nanosonics Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

43.19%Per cent of shares held by top holders
HolderShares% Held
Selector Funds Management Ltd.as of 31 Jul 202524.24m7.99%
Hyperion Asset Management Ltd.as of 21 Oct 202519.63m6.47%
Yarra Funds Management Ltd.as of 31 Jul 202516.01m5.28%
UBS Asset Management (Australia) Ltd.as of 25 Nov 202515.27m5.03%
ECP Asset Management Pty Ltd.as of 21 Mar 202515.15m4.99%
First Sentier Investors (Australia) IM Ltd.as of 17 Dec 202412.74m4.20%
The Vanguard Group, Inc.as of 04 Feb 20269.45m3.12%
State Street Global Advisors, Australia, Ltd.as of 26 Sep 20246.91m2.28%
Vanguard Investments Australia Ltd.as of 31 Dec 20255.91m1.95%
Australian Foundation Investment Co. Ltd. (Invt Mgmt)as of 31 Jul 20255.72m1.88%
More ▼
Data from 30 Jun 2025 - 13 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.